Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT06219356 is registered in ClinicalTrials.gov with Hangzhou GluBio Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06219356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06219356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Lead sponsor
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 11, 2024
Completion date
February 28, 2027
Enrollment
110 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma